La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Medacta Group Croissance future
Future contrôle des critères 3/6
Medacta Group devrait augmenter ses bénéfices et son chiffre d'affaires de 20% et de 11.6% par an respectivement. Le BPA devrait croître de de 23.2% par an. Le rendement des capitaux propres devrait être 19.8% dans 3 ans.
Informations clés
18.8%
Taux de croissance des bénéfices
21.8%
Taux de croissance du BPA
| Medical Equipment croissance des bénéfices | 15.0% |
| Taux de croissance des recettes | 12.0% |
| Rendement futur des capitaux propres | 20.0% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 26 Sep 2024 |
Mises à jour récentes de la croissance future
Recent updates
Medacta Group SA (VTX:MOVE) Shares Could Be 32% Above Their Intrinsic Value Estimate
Sep 06
What Does Medacta Group SA's (VTX:MOVE) Share Price Indicate?
Aug 21Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return
Aug 06Medacta Group SA's (VTX:MOVE) P/E Still Appears To Be Reasonable
Jun 20We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year
May 01Medacta Group (VTX:MOVE) Has A Pretty Healthy Balance Sheet
Apr 17Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?
Mar 29Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?
Feb 22Medacta Group (VTX:MOVE) Will Be Hoping To Turn Its Returns On Capital Around
Feb 07Getting In Cheap On Medacta Group SA (VTX:MOVE) Might Be Difficult
Dec 18Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)
Dec 04Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?
Nov 15Returns On Capital Signal Tricky Times Ahead For Medacta Group (VTX:MOVE)
Oct 30If EPS Growth Is Important To You, Medacta Group (VTX:MOVE) Presents An Opportunity
Oct 17Is Medacta Group (VTX:MOVE) Using Too Much Debt?
Sep 29Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)
Aug 11Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?
Jul 27Be Wary Of Medacta Group (VTX:MOVE) And Its Returns On Capital
Jul 03At CHF117, Is It Time To Put Medacta Group SA (VTX:MOVE) On Your Watch List?
Apr 28Is Medacta Group (VTX:MOVE) A Risky Investment?
Apr 08Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?
Dec 25Capital Allocation Trends At Medacta Group (VTX:MOVE) Aren't Ideal
Dec 09Does Medacta Group (VTX:MOVE) Have A Healthy Balance Sheet?
Nov 09Why Medacta Group SA (VTX:MOVE) Could Be Worth Watching
Sep 16The Returns On Capital At Medacta Group (VTX:MOVE) Don't Inspire Confidence
Aug 20Here's Why Medacta Group (VTX:MOVE) Has Caught The Eye Of Investors
Jul 02Should You Think About Buying Medacta Group SA (VTX:MOVE) Now?
May 28Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return
May 12These 4 Measures Indicate That Medacta Group (VTX:MOVE) Is Using Debt Reasonably Well
Mar 31Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?
Mar 17Capital Investments At Medacta Group (VTX:MOVE) Point To A Promising Future
Feb 07Should You Investigate Medacta Group SA (VTX:MOVE) At CHF133?
Dec 10Medacta Group (VTX:MOVE) Knows How To Allocate Capital
Nov 05Here's Why Medacta Group (VTX:MOVE) Can Manage Its Debt Responsibly
Sep 30Is It Too Late To Consider Buying Medacta Group SA (VTX:MOVE)?
Aug 26Medacta Group (VTX:MOVE) May Have Issues Allocating Its Capital
Jul 20Should You Investigate Medacta Group SA (VTX:MOVE) At CHF119?
May 19We Think Medacta Group (VTX:MOVE) Can Stay On Top Of Its Debt
Apr 05What You Need To Know About Medacta Group SA's (VTX:MOVE) Investor Composition
Mar 02Is Medacta Group SA's (VTX:MOVE) 7.6% ROE Better Than Average?
Feb 02The Medacta Group (VTX:MOVE) Share Price Has Gained 24% And Shareholders Are Hoping For More
Jan 12
Returns On Capital At Medacta Group (VTX:MOVE) Paint An Interesting Picture
Dec 21Should You Use Medacta Group's (VTX:MOVE) Statutory Earnings To Analyse It?
Dec 03Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 744 | 99 | 48 | 150 | 7 |
| 12/31/2025 | 664 | 84 | 38 | 146 | 7 |
| 12/31/2024 | 579 | 75 | 24 | 123 | 2 |
| 6/30/2024 | 544 | 56 | -14 | 80 | N/A |
| 3/31/2024 | 528 | 52 | -10 | 77 | N/A |
| 12/31/2023 | 511 | 47 | -6 | 75 | N/A |
| 9/30/2023 | 496 | 49 | 2 | 78 | N/A |
| 6/30/2023 | 481 | 50 | 9 | 80 | N/A |
| 3/31/2023 | 459 | 48 | 8 | 77 | N/A |
| 12/31/2022 | 437 | 46 | 7 | 74 | N/A |
| 9/30/2022 | 417 | 47 | 4 | 72 | N/A |
| 6/30/2022 | 397 | 47 | 2 | 70 | N/A |
| 3/31/2022 | 380 | 49 | 1 | 62 | N/A |
| 12/31/2021 | 363 | 52 | -1 | 54 | N/A |
| 9/30/2021 | 354 | 54 | 11 | 58 | N/A |
| 6/30/2021 | 345 | 57 | 22 | 63 | N/A |
| 3/31/2021 | 324 | 47 | 22 | 61 | N/A |
| 12/31/2020 | 302 | 37 | 22 | 60 | N/A |
| 9/30/2020 | 298 | 24 | 9 | 50 | N/A |
| 6/30/2020 | 294 | 10 | -5 | 40 | N/A |
| 3/31/2020 | 302 | 11 | -7 | 41 | N/A |
| 12/31/2019 | 311 | 12 | -9 | 43 | N/A |
| 9/30/2019 | 301 | 22 | -3 | 46 | N/A |
| 6/30/2019 | 291 | 33 | 3 | 50 | N/A |
| 3/31/2019 | 282 | 39 | 7 | 58 | N/A |
| 12/31/2018 | 273 | 46 | 11 | 66 | N/A |
| 12/31/2017 | 245 | 33 | N/A | 52 | N/A |
| 12/31/2016 | 219 | 39 | N/A | 56 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de MOVE ( 20% par an) est supérieure au taux d'épargne ( 0.3% ).
Bénéfices vs marché: Les bénéfices de MOVE ( 20% par an) devraient croître plus rapidement que le marché Swiss ( 11.9% par an).
Croissance élevée des bénéfices: Les bénéfices de MOVE devraient augmenter, mais pas de manière significative.
Chiffre d'affaires vs marché: Le chiffre d'affaires de MOVE ( 11.6% par an) devrait croître plus rapidement que le marché Swiss ( 4.4% par an).
Croissance élevée des revenus: Le chiffre d'affaires de MOVE ( 11.6% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de MOVE devrait être faible dans 3 ans ( 19.8 %).